IL1B
Interleukin-1 beta
As of the edition of 20 October 2026, IL1B (interleukin-1 beta, UniProt P01584) has 7 drugs tested at it and 8 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P01584
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 64
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Inherited and neonatal; Nutrition and metabolism; Lungs and airways; Cancer; Heart and blood vessels
- Registered trials of its drugs
- 161
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 3 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Canakinumab | Marketed | Phase 4 | Ends 2027 |
| Rilonacept | Marketed | Phase 4 | Ends 2028 |
| Gevokizumab | Stopped | Phase 3 | none listed |
| Lutikizumab | Active | Phase 3 | none listed |
| HU007 | Active | Phase 3 | none listed |
| SSGJ-613 | Active | Phase 2 | none listed |
| TAVO103A | Status not established | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Novartis | Route B |
| Regeneron | Route A |
| Kiniksa Pharmaceuticals | Route B |
The other 5 companies at IL1B
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at IL1B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.